Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORA-4: lisaftoclax plus azacitidine versus placebo plus azacitidine in newly diagnosed higher-risk myelodysplastic syndrome
2024-517247-31-00Phase 3Authorised
- Sponsor
- Ascentage Pharma
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Lisaftoclax + azacitidine with Placebo + azacitidine (2 arms). Planned start Jul 2025; status: authorised.
02
Drugs
lisaftoclaxazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2024-517247-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517247-31-00.